40 results on '"Kunadt, Desiree"'
Search Results
2. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia
3. Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT
4. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
5. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party
6. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
7. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
8. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
9. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
10. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
11. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
12. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation.
13. Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia
14. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
15. Multidrug-related protein 1 (MRP1) polymorphisms rs129081, rs212090, and rs212091 predict survival in normal karyotype acute myeloid leukemia
16. Germline variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
17. P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
18. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
19. Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia
20. Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.
21. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
22. Fascia training in patients undergoing allogeneic hematopoietic cell transplantation—a pilot study
23. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
24. sj-docx-1-tah-10.1177_20406207221115005 – Supplemental material for Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
25. Additional file 1 of Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
26. Additional file 1 of Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
27. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
28. Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
29. Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
30. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
31. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia
32. Impact of KMT2A-PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation
33. Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De Novo AML: A Study from the ALWP/EBMT
34. Unrelated Donors below 35 Years of Age Should be Preferred over HLA-Matched Sibling Donors Older Than 50 Years for Patients with Myeloid Malignancies
35. Haploidentical transplantation in primary refractory/relapsed secondary versus de novoAML: from the ALWP/EBMT
36. Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Relapsed/Refractory Secondary Versus De NovoAML: A Study from the ALWP/EBMT
37. Multidrug-Related Protein 1 (MRP1) Polymorphisms rs129081, rs212090, and rs212091 Predict Survival In Acute Myeloid Leukemia
38. Differential impact of IDH1/2mutational subclasses on outcome in adult AML: Results from a large multicenter study
39. Profound sympathetic neuropathy in the bone marrow of patients with acute myeloid leukemia.
40. Influence of invasive aspergillosis during acute leukaemia treatment on survival after allogeneic stem cell transplantation: a prospective study of the EBMT Infectious Diseases Working Party.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.